In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
IsraelWithdrawnPHASE1, PHASE2
Conditions
Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Study leads
Michael Har-Noy
Study Director
Mirror Biologics, Inc.